Press release
BRAF-mutant Non-Small Cell Lung Cancer Pipeline Insights, Clinical Trials, Treatment Drugs and Companies 2024
BRAF-mutant Non-Small Cell Lung Cancer Pipeline
Explore our latest breakthroughs in BRAF-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ BRAF-mutant Non-Small Cell Lung Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• In August 2024:- Novartis Pharmaceuticals- The purpose of this study is to evaluate the safety and efficacy of dabrafenib in combination with trametinib in Chinese patients with BRAF V600E mutation-positive metastatic Non-Small Cell Lung Cancer. The general study design has been discussed and agreed with Chinese Health Authority and is applying a similar design used for global pivotal phase II study (BRF113928).
• In August 2024:- Immuneering Corporation- The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-6-415 to further explore the anti-tumor activity of IMM-6-415 as monotherapy in Phase 2a tumor-specific cohorts. Patients will be self-administering IMM-6-415 on a daily basis for up to 16 cycles (21-day cycles). During the first 2 cycles, PK and PD will be assessed. Solid tumor types with RAS/RAF mutations are eligible.
• DelveInsight's BRAF-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF-mutant Non-Small Cell Lung Cancer treatment.
• The leading BRAF-mutant Non-Small Cell Lung Cancer Companies such as Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
• Promising BRAF-mutant Non-Small Cell Lung Cancer Therapies such as IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.
Stay informed about the cutting-edge advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ BRAF-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile
• Encorafenib/Binimetinib: Pierre Fabre Medicament
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.
• XP-102: Xynomic Pharmaceuticals, Inc.
XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.
Learn more about BRAF-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking BRAF-mutant Non-Small Cell Lung Cancer Research and development projects @ BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
BRAF-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Discover the latest advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ BRAF-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• BRAF-mutant Non-Small Cell Lung Cancer Companies- Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapies- IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of BRAF-mutant Non-Small Cell Lung Cancer Pipeline on our website @ BRAF-mutant Non-Small Cell Lung Cancer Drugs and Companies- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. BRAF-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Encorafenib/Binimetinib: Pierre Fabre Medicament
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. XP-102: Xynomic Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
21. BRAF-mutant Non-Small Cell Lung Cancer Key Products
22. BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
26. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix
List of Top Selling Market Research Report in 2024
Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Pacemakers Market- https://www.delveinsight.com/report-store/pacemakers-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Intraocular Lymphoma Market- https://www.delveinsight.com/report-store/intraocular-lymphoma-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Transcatheter Heart Valve Replacement Devices Market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
Endoscopic Ultrasound Market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Trichomoniasis Market- https://www.delveinsight.com/report-store/trichomoniasis-market-insights
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
CXCR Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Pigment Epithelial Detachment Market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BRAF-mutant Non-Small Cell Lung Cancer Pipeline Insights, Clinical Trials, Treatment Drugs and Companies 2024 here
News-ID: 3663355 • Views: …
More Releases from DelveInsight Business Research LLP
Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials, Treatment Drugs, Pip …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Postoperative acute pain Market Size is Set for Rapid Growth as Innovative Treat …
The market size of Postoperative acute pain is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Taiwan Liposome Company (TLC)., Teikoku Pharma, Concentric Analgesics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Avenue Therapeutics, Cali Pharmaceuticals LLC
[Nevada, United States] - DelveInsight's "Postoperative acute pain Market Insights, Epidemiology, and Market Forecast 2034."…
Oligometastatic Disease Market Size is Set for Rapid Growth as Innovative Treatm …
The Oligometastatic Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company
[Nevada, United States] - DelveInsight's "Oligometastatic Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Oligometastatic Disease, covering historical and predicted epidemiology, market trends, and treatment…
PD-1 Non-Small Cell Lung Cancer Market Size is Set for Rapid Growth as Innovativ …
The PD-1 Non-Small Cell Lung Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic,, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb
[Nevada, United States] - DelveInsight's "PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast 2034."…
More Releases for BRAF
BRAF Kinase Inhibitors Market Generated Opportunities, Future Scope 2022-2028 | …
The BRAF Kinase Inhibitors Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this BRAF Kinase Inhibitors Market report is to supply an in-depth view and strategic analysis of the parent industry. The report examines each segment also as their respective sub-segments present within the market in an all-inclusive manner. The report provides…
BRAF Kinase Inhibitors Market Trends, Growth, Size, Share, Demand and Forecast t …
BRAF Kinase Inhibitors Market Introduction
BRAF is a human gene that encodes the BRAF protein. The BRAF protein is more formally known as serine/threonine-protein kinase BRAF. The BRAF gene is also known as VRAF murine sarcoma viral oncogene homolog B and proto-oncogene BRAF. BRAF is a member of the RAF kinase family of growth signal transduction protein kinases. These proteins play an important role in regulating the MAP kinase signaling pathway.…
Global BRAF Kinase Inhibitors Market Size, Share and Forecast 2021-2027
The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to…
BRAF Kinase Inhibitors Market Size and Growth by Major Companies, Regions, Types …
BRAF Kinase Inhibitors Market 2021-2027 Research Report provides a detailed analysis of global braf kinase inhibitors industry competition, driving forces, trends, opportunities, challenges, risks, sales channels, distributors and analysis of Porter’s five forces. This braf kinase inhibitors report examines the market size of BRAF Kinase Inhibitors Market by the top player, regions, array type, measurement, application, and industry.
Download Sample Copy of this Report @ https://adhocindustryanalytics.com/request_sample?reportId=83&industryId=6
With the clear insight this report…
BRAF-MEK Inhibitors Market Ongoing Trends, Recent Developments & Forecast till 2 …
The global BRAF-MEK Inhibitors market study covers the projection size of the market both in terms of value and volume.
The report estimates the lookup of different local distributors in the overall market and provides the market size of the BRAF-MEK Inhibitors market using both bottom-up and top-down approaches.
To get in-depth information view the report – https://www.factmr.com/report/braf-mek-inhibitors-market
To investigate the key players and their market contribution, primary and secondary research has been…
Global BRAF Kinase Inhibitors Market to Witness a Pronounce Growth During 2024
LP INFORMATION offers a latest published report on BRAF Kinase Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the BRAF Kinase Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
